OneCell Diagnostics bags $16M to help limit cancer reoccurrence using AI | TechCrunch
Briefly

"OneCell's blood-based biopsy tests can detect cancer recurrence with 100 times more information than conventional liquid biopsies, revolutionizing diagnosis in precision oncology."
"The startup focuses on isolating circulating tumor cells from blood samples, offering insights into cancer recurrence that traditional methods like PET scans cannot provide."
Read at TechCrunch
[
|
]